To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma.
Phase:
PHASE3
Details
Lead Sponsor:
Lai-ping Zhong
Collaborators:
Central South University Fudan University Fujian Medical University Sun Yat-sen University